Testosterone enanthate therapy is effective and independent of SRD5A2 and AR gene polymorphisms in boys with micropenis

被引:16
|
作者
Ishii, T
Sasaki, G
Hasegawa, T
Sato, S
Matsuo, N
Ogata, T
机构
[1] Natl Res Inst Child Hlth & Dev, Dept Endocrinol & Metab, Tokyo 1548567, Japan
[2] Keio Univ, Sch Med, Dept Pediat, Tokyo 108, Japan
来源
JOURNAL OF UROLOGY | 2004年 / 172卷 / 01期
关键词
penis/abnormalities; testosterone; 5-alpha-reductase; polymorphism (genetics);
D O I
10.1097/01.ju.0000129005.84831.1e
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We report penile length (PL) responses to testosterone enanthate (TE) therapy for micropenis, and the relevance of the V89L polymorphism of SRD5A2 encoding the 5alpha-reductase type 2 and CAG repeat length polymorphism of AR encoding the androgen receptor. Materials and Methods: A total of 53 Japanese boys with micropenis (less than -2.0 SD) 0 to 13 years old who had no SRD5A2 or AR mutation were examined. TE was given at a dosage of 25 mg intramuscularly, and PL was measured at least 4 weeks after the injection. The 2 polymorphisms were determined by direct sequencing. Results: PLs became -2.0 SD or greater in all the boys after TE therapy (1 injection in 4 boys, 2 in 28, 3 in 19 and 4 in 2), with a significant increase in the medians of PLs (from 2.5 to 3.5 cm, p <0.0001) and SD score, (from -2.6 to -0.7, p <0.0001). The increment in actual PL at the first injection ranged from 0.2 to 1.5 cm (median 0.6) and was independent of age (r = 0.22, p = 0.12) and body surface area (r = 0.11, p =0.43), while that in PL SD score at the first injection ranged from 0.3 to 2.5 (1.0) and was inversely correlated with age (r = -0.33, p = 0.02) and body surface area (r = -0.37, p = 0.008). The actual PL increment at the first injection was also unrelated to initial PL (r = -0.03, p = 0.81). The median of actual PL increments at the first injection was similar among boys with V/V, V/L and L/L genotypes of SRD5A2 (0.6 cm in 18, 0.7 cm in 30 and 0.5 cm in 5, respectively, p = 0.77), and between boys with and without long CAG repeats (26 or greater) of AR (0.65 cm in 6 and 0.6 cm in 47, respectively, p = 0.77). In addition, there was no significant correlation between actual PL increment at the first injection and CAG repeat length (r = 0.06, p = 0.67). Conclusions: Our results suggest that administration of 25 mg TE is effective for micropenis in prepubertal boys with no SRD5A2 or AR mutation, with variable but significant PL increments, and that the penile responsiveness to TE therapy is independent of the V89L and the CAG repeat length polymorphisms.
引用
收藏
页码:319 / 323
页数:5
相关论文
共 50 条
  • [21] Association of SRD5A2 gene mutations with risk of hypospadias in the Iranian population
    M. Rahimi
    M. Ghanbari
    Z. Fazeli
    M. Rouzrokh
    S. Omrani
    R. Mirfakhraie
    M. D. Omrani
    Journal of Endocrinological Investigation, 2017, 40 : 391 - 396
  • [22] Associations between polymorphisms in the steroid 5α-reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer
    Salam, MT
    Ursin, G
    Skinner, EC
    Dessissa, T
    Reichardt, JK
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 374 - 374
  • [23] Association of 5-alpha-reductase gene (SRD5A2) with prostate cancer.
    Mononen, N
    Koivisto, PA
    Ikonen, T
    Syrjäkoski, K
    Schleutker, J
    Hyytinen, E
    Tammela, TLJ
    Kallioniemi, OP
    AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (04) : 95 - 95
  • [24] Development of CRISPR-Cas12f Gene Therapy for Androgenic Alopecia via Targeting of SRD5A2 Gene
    Kang, Suyeon
    Kang, Seunghun
    Bae, Taegeun
    Hur, Junho
    MOLECULAR THERAPY, 2023, 31 (04) : 736 - 736
  • [25] Associations between polymorphisms in the steroid 5-α reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer
    Salam, MT
    Ursin, G
    Skinner, EC
    Dessissa, T
    Reichardt, JKV
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2005, 23 (04) : 246 - 253
  • [26] Molecular analysis of the AR and SRD5A2 genes in patients with 46,XY disorders of sex development
    Choi, Jin-Ho
    Kim, Gu-Hwan
    Seo, Eul-Ju
    Kim, Kun-Suk
    Kim, Sung Hoon
    Yo, Han-Wook
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2008, 21 (06): : 545 - 553
  • [27] A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH
    Klotsman, M
    Weinberg, CR
    Davis, K
    Binnie, CG
    Hartmann, KE
    PHARMACOGENOMICS JOURNAL, 2004, 4 (04): : 251 - 259
  • [28] A case-based evaluation of SRD5A1, SRD5A2, AR, and ADRA1A as candidate genes for severity of BPH
    M Klotsman
    C R Weinberg
    K Davis
    C G Binnie
    K E Hartmann
    The Pharmacogenomics Journal, 2004, 4 : 251 - 259
  • [29] The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism
    Shiota, M.
    Fujimoto, N.
    Yokomizo, A.
    Takeuchi, A.
    Kashiwagi, E.
    Dejima, T.
    Kiyoshima, K.
    Inokuchi, J.
    Tatsugami, K.
    Eto, M.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (02) : 191 - 196
  • [30] SRD5A2 and HSD3B2 Polymorphisms are associated with prostate cancer risk and aggressiveness
    Neslund-Dudas, Christine
    Bock, Cathryn H.
    Monaghan, Kristin
    Nock, Nora L.
    Yang, James J.
    Rundle, Andrew
    Tang, Deliang
    Rybicki, Benjamin A.
    PROSTATE, 2007, 67 (15): : 1654 - 1663